Spectranetics Concludes LARS Trial
COLORADO SPRINGS, Colo., Nov. 28 -- The Spectranetics Corp. said it is concluding its LARS (laser angioplasty for restenosed stents) clinical trial, in light of recent approval from the FDA to market its products to clear clogged coronary stents (thin steel mesh tubes used to support the walls of arteries) prior to radiation treatment.
The company will continue to follow all 138 LARS patients through the study's nine-month follow-up period. It said its clinical priorities for 2002 continue to be accelerating PELA and LACI clinical trials involving excimer laser energy to clear blockages in leg arteries.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024